EBV VCA IgM ELISA Kit

Catalog No. ABIN1326839

Product Details EBV VCA IgM ELISA Kit

Target: EBV VCA IgM (Anti-Epstein-Barr Virus Viral Capsid Antigen IgM (EBV VCA IgM))

Reactivity: Human

Detection Method: Colorimetric

Method Type: Competition ELISA

Application: ELISA

Purpose: Diluted patient serum (serum diluent contains sorbent to remove rheumatoid factor and human IgG interference) is added to wells coated with purified antigen. IgM specific antibody, if present, binds to the antigen. All unbound materials are washed away and the enzyme conjugate is added to bind to the antibody-antigen complex, if present. Excess enzyme conjugate is washed off and substrate is added. The plate is incubated to allow the hydrolysis of the substrate by the enzyme. The intensity of the color generated is proportional to the amount of IgM specific antibody in the sample.

Sample Type: Serum

Analytical Method: Qualitative

Application Details

Plate: Pre-coated

Restrictions: For Research Use only

Handling

Storage: 4 °C

Target Details for EBV VCA IgM

Target: EBV VCA IgM (Anti-Epstein-Barr Virus Viral Capsid Antigen IgM (EBV VCA IgM))

Alternative Name: EBV-VCA IgM (EBV VCA IgM Products)

Target Type: Antibody, Antibody

Background: Epstein-Barr virus (EBV) is a herpes virus known to cause infectious mononucleosis (IM). EBV infection may demonstrate a wide spectrum of clinical symptoms. The majorities of primary EBV infections are transmitted via saliva, occur during childhood, and are sub-clinical. In the U.S., 50% of the population demonstrate EBV antibodies before the age of 5 years 80% by adulthood. Transfusion-associated EBV infections have also been reported. Epstein-Barr virus has also been associated in the pathogenisis of two human cancers, Burkitt's lymphoma and nasopharyngeal carcinoma. Burkitt's lymphoma is primarily observed in Sub-Sahara Africa, especially in African children, and in New Guinea. Nasopharyngeal carcinoma is observed in Asia, most notably in Southern China.